XML 36 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Intangible Assets and Goodwill
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets
Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:
  As of September 30, 2024As of December 31, 2023
(In millions)Estimated LifeCostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
Completed technology:
Acquired and in-licensed rights and patents
2-21 years
$10,552.9 $(2,697.9)$7,855.0 $8,180.2 $(2,440.7)$5,739.5 
Developed technology and other
13-31 years
3,548.6 (3,445.0)103.6 3,548.6 (3,429.1)119.5 
Total completed technology14,101.5 (6,142.9)7,958.6 11,728.8 (5,869.8)5,859.0 
In-process research and developmentIndefinite until commercialization1,682.9 — 1,682.9 2,340.0 — 2,340.0 
Priority review voucherIndefinite100.0 — 100.0 100.0 — 100.0 
Trademarks and trade namesIndefinite64.0 — 64.0 64.0 — 64.0 
Total intangible assets$15,948.4 $(6,142.9)$9,805.5 $14,232.8 $(5,869.8)$8,363.0 
Amortization and Impairments
For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets, totaled $130.3 million and $295.5 million, respectively, compared to $60.9 million and $164.0 million, respectively, in the prior year comparative periods.
For the three and nine months ended September 30, 2024, amortization of acquired intangible assets, excluding impairment charges, totaled $110.1 million and $275.3 million, respectively, compared to $60.9 million and $164.0 million, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the Reata acquisition acquired intangible assets associated with SKYCLARYS.
For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of $20.2 million, related to intangible assets associated with Samsung Bioepis commercialization rights terminated during the third quarter of 2024. For the three and nine months ended September 30, 2023, we had no impairment charges.
For additional information on our 2019 Development and Commercialization Agreement with Samsung Bioepis, please read Note 19, Collaborative and Other Relationships, to these condensed consolidated financial statements.
Completed Technology
Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 13 years for acquired and in-licensed rights and patents and 10 years for developed technology and other. In connection with our acquisition of Reata in September 2023 we acquired SKYCLARYS, a commercially-approved product in the U.S., with an estimated fair value of approximately $4.2 billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset, with an estimated fair value of approximately $2.3 billion, from IPR&D to completed technology.
IPR&D Related to Business Combinations
IPR&D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&D balances are adjustments related to foreign currency exchange rate fluctuations.
The carrying value associated with our IPR&D assets as of December 31, 2023, related to the IPR&D programs we acquired in connection with our acquisition of Reata in September 2023, with an estimated fair value of approximately $2.3 billion, which includes measurement period adjustments. During the first quarter of 2024 SKYCLARYS was approved in the E.U. and became commercially available, which resulted in the reclassification of the related intangible asset from IPR&D to completed technology.
The carrying value associated with our IPR&D assets as of September 30, 2024, primarily relates to the IPR&D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately $1.6 billion.
Priority Review Voucher
In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV that may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the priority review voucher based on its estimated fair value of $100.0 million as an intangible asset. The estimated fair value was based on recent external purchase and sale transactions of similar vouchers.
For additional information on our acquisitions of Reata and HI-Bio, please read Note 2, Acquisitions, to these condensed consolidated financial statements.
Estimated Future Amortization of Intangible Assets
The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:
(In millions)As of September 30, 2024
2024 (remaining three months)$125.0 
2025510.0 
2026550.0 
2027585.0 
2028615.0 
2029655.0 
Goodwill
The following table provides a roll forward of the changes in our goodwill balance:
(In millions)As of September 30, 2024
Goodwill, December 31, 2023$6,219.2 
Goodwill resulting from HI-Bio acquisition256.5 
Goodwill resulting from Reata acquisition(1)
4.7 
Other5.4 
Goodwill, September 30, 2024$6,485.8 
(1) Relates to Reata measurement period adjustments recognized during the nine months ended September 30, 2024.
For additional information on our acquisitions of Reata and HI-Bio, please read Note 2, Acquisitions, to these condensed consolidated financial statements.
As of September 30, 2024, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.